awmsg logo



ulipristal acetate (Esmya®)


Reference No. 1575

Publication date:
15/08/2013


Last review date:
30/09/2016

Appraisal information

ulipristal acetate (Esmya®) 5 mg tablet


Company: Gedeon Richter UK Ltd
BNF category: Endocrine system
NMG meeting date: 19/06/2013
AWMSG meeting date: 17/07/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1913
Ministerial ratification: 14/08/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ulipristal acetate (Esmya®) is recommended as an option for use within NHS Wales for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The duration of treatment is limited to three months.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download